Pharma Focus Asia
KP - Choose our fully recyclable blister films

Jacobio Pharma Introduces Novel KRAS G12C Inhibitor Glecirasib for Pancreatic Cancer

Jacobio Pharma has introduced an innovative in-house solution with the KRAS G12C inhibitor, Glecirasib, aimed at treating patients with pancreatic cancer.

Glecirasib is specifically designed for patients with pancreatic cancer who possess the KRAS G12C mutation and have experienced progression after undergoing standard frontline treatments. 

This groundbreaking inhibitor is currently being assessed in Phase I/II clinical trials across China, the United States, and Europe. These trials target individuals with advanced solid tumours that carry the KRAS G12C mutation. 

A pivotal clinical trial is also in progress, focusing on evaluating the effectiveness and safety of Glecirasib as a single-agent treatment for locally advanced or metastatic pancreatic cancer in patients with the KRAS G12C mutation. 

This trial includes research in China for non-small cell lung cancer (NSCLC) as well as studies involving monotherapy for STK11 co-mutated NSCLC in the front-line setting. Additionally, combination therapy trials involving the SHP2 inhibitor JAB-3312 in NSCLC and Cetuximab in colourectal cancer are being conducted.

Pancreatic cancer is known for its aggressive nature and limited treatment options. Currently, the five-year overall survival rate stands at a mere 5 percent.

Glecirasib, a KRAS G12C inhibitor, has secured breakthrough therapy designation from China Centre for Drug Evaluation (CDE) for pancreatic cancer treatment.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024